The Central Drugs Standard Control Organisation (CDSCO) granted marketing authorisation in India to Sanofi's Qfitlia (fitusiran) on 21 October 2026.
It is approved for routine prophylaxis — regular preventive dosing — against bleeding in people aged 12 and above with haemophilia A or B, with or without factor VIII/IX inhibitors.
Qfitlia is the first antithrombin-lowering therapy approved in India: a small interfering RNA (siRNA) that lowers antithrombin so the blood generates more thrombin.
It needs as few as six injections a year; approval rests on the ATLAS phase 3 programme. The US FDA approved it on 28 March 2025 and China in December 2025.
Antithrombin is the body's natural brake on clotting enzymes thrombin and factor Xa. Standard haemophilia care replaces the missing factor VIII or IX. Fitusiran instead lowers antithrombin, so more thrombin forms and clotting rebalances — which is why it works whether or not inhibitors are present.
Simple Analogy: Instead of adding a missing accelerator, it eases off the brake.
US FDA approves Qfitlia for haemophilia A or B prophylaxis, age 12+
China's National Medical Products Administration approves Qfitlia
CDSCO grants Indian marketing authorisation
National drug regulator under the Ministry of Health and Family Welfare; approves new drugs and clinical trials, regulates import, manufacture and sale
US drug regulator; approved Qfitlia first, in March 2025
Parent law under which CDSCO and the DCGI regulate drugs in India
Govern marketing authorisation of a new drug such as fitusiran and the trials behind it
Lists haemophilia, thalassaemia and sickle cell disease under 'blood disorders' among its 21 recognised disabilities
GS Paper 3 > Science and Technology > Biotechnology, RNA-based therapeutics; GS Paper 2 > Health
General Science > Human blood and diseases
Small interfering RNA — a short RNA that switches off a target gene by destroying its messenger RNA (RNA interference).
Regular treatment given to prevent bleeds, not to treat one already under way.
An antibody against infused replacement factor that makes standard therapy fail.